LBA1 Final analysis of the placebo-controlled randomised phase III IMpassion031 trial evaluating neoadjuvant atezolizumab (atezo) plus chemotherapy (CT) followed by open-label adjuvant atezo in patients (pts) with early-stage triple-negative breast cancer (eTNBC)

Autor:	C. Barrios, N. Harbeck, H.A. Zhang, S. Saji, K.H. Jung, R. Hegg, A. Koehler, J. Sohn, H. Iwata, M.L. Telli, J-F. Boileau, K. Punie, M. Dieterich, Z.J.F. Assaf, T. Xu, M. Liste Hermoso, E. Shearer-Kang, L. Molinero, S.Y. Chui, E.A. Mittendorf
Rok vydání:	2023
Předmět:	Cancer Research Oncology
Zdroj:	ESMO Open. 8:101571
ISSN:	2059-7029
DOI:	10.1016/j.esmoop.2023.101571
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::87309ad84d635f74f4c38288490f629b https://doi.org/10.1016/j.esmoop.2023.101571 Zobrazit plný text záznamu